4 ms·
It has done this with US$290 million — about one-quarter of what a typical pharmaceutical company would spend to develop just one drug What a poorly researched
by refurb 9y ago
It has done this with US$290 million — about one-quarter of what a typical pharmaceutical company would spend to develop just one drug
What a poorly researched article.
Of course they have. If you only measure the successful drugs, the cost of R&D is much lower. The question is, how do you identify those drugs?
Plus, DNDi is not creating brand new molecules. Their molecules are either:(1) old drugs that we already know work but were never formally approved, (2) cast-off drugs where someone already spent a shit-ton of money, but never took them to the finish line or (3) me-too drugs, where they just tweak a known drug. All of those are much lower risk than creating a brand new drug with a new MOA.
When they come up with a new drug with a truly novel mechanism, then we can find out how much it cost them.
Derek Lowe from the "In the pipeline" blog put it well:
"As pointed out in that previous post, the initiative, for the most part, is repurposing drugs that were discovered and at least partially developed by someone else, using someone else’s time, money, expertise and infrastructure."[1]
[1]http://blogs.sciencemag.org/pipeline/archives/2016/08/26/gosh-fellows-theres-a-better-way http://blogs.sciencemag.org/pipeline/archives/2016/08/26/gos...
- jopsen 9y agoIsn't most drug developments just incremental improvements on previous drugs? Don't most drug companies stand on the shoulders of giants, starting of from public basic research?
- refurb 9y agoIt's very rare that someone does everything from the basic science to approval. However, there are varying degrees of incremental. I would say DNDi is on the very incremental end.